A 64-year-old man presented with an initially transient but later persistent facial edema for the past five years. Dermatological examination revealed poorly defined areas of erythema and non-pitting edema on the upper face and eyelids (Fig. 1). Laboratory and imaging studies were unremarkable. A skin biopsy revealed edema and superficial dermal vascular ectasia with mild lympho-histiocytic perivascular infiltrate with mast cells (Fig. 2), suggestive of Morbihan disease. Sequential treatment with isotretinoin (10 mg/day) and bilastine (20 mg/day) for four months followed by isotretinoin (20 mg/day) and prednisolone (10 mg/day) for three months was attempted, without significant benefit. Later on, doxycycline...

(100 mg/day) was initiated, with mild improvement after two months translating into a significant improvement in the quality of life.

Morbihan disease is considered a late stage of rosacea and is characterized by non-pitting facial edema. The lack of pathognomonic clinical or histopathological features makes this a challenging and frequently delayed diagnosis. Given its rarity, no guidelines are available regarding its management. Patients are generally treated with systemic corticosteroids, antibiotics, and/or isotretinoin, often with unsatisfactory results. Further studies are required to define an optimal therapeutic approach.

AUTHOR CONTRIBUTIONS
All authors contributed equally to this manuscript.

PROTECTION OF HUMANS AND ANIMALS
The authors declare that the procedures were followed according to the regulations established by the Clinical Research and Ethics Committee and to the Helsinki Declaration of the World Medical Association updated in 2013.

DATA CONFIDENTIALITY
The authors declare having followed the protocols in use at their working center regarding patients’ data publication.

PATIENT CONSENT
Obtained.

COMPETING INTERESTS
The authors have declared that no competing interests exist.

FUNDING SOURCES
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

REFERENCES